Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01407094 · ClinicalTrials.gov registry record · Phase 2
Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care for Depression
A Phase 2 study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 296
- Enrollment target
NCT01407094 is a Phase 2 study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 296 participants.
The verdict
NCT01407094, a Phase 2 study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 296 participants
- Enrollment target
Study Summary
This study will examine multiple carefully selected clinical and biological markers, using both existing state-of-the-art technologies as well as pioneering, innovative approaches. The study is designed to identify moderators and mediators of treatment response for depression in order to specify a biosignature of treatment response for depression. Evaluation of the usefulness of these markers in a carefully conducted clinical trial comparing an antidepressant to placebo will assist in developing a Depression Treatment Response Index (DTRI) to help clinicians match treatments to patients with MDD, resulting in timely selection of treatments best suited for individual patients and thus approaching personalized treatment. The resulting index provides a truly novel means of synthesizing the contribution of key clinical and biological parameters in an easy to use tool for clinical care.
Interventions
- DRUG Placebo
- DRUG Sertraline
- DRUG BupropionXL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 296 participants |
| Start Date | 2011-07-29 |
| Est. Completion | 2016-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01407094
The ClinicalTrials.gov registry entry for NCT01407094 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 296 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01407094 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01407094 about?
NCT01407094 is a clinical study titled "Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care for Depression". This study will examine multiple carefully selected clinical and biological markers, using both existing state-of-the-art technologies as well as pioneering, innovative approaches. The study is designed to identify moderators and mediators of treatment response for depression in order to specify a b...
What is the current status of trial NCT01407094?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 296 participants. The study started on 2011-07-29. Estimated completion is 2016-04.
What interventions are being tested in trial NCT01407094?
The interventions under investigation include: Placebo (DRUG), Sertraline (DRUG), BupropionXL (DRUG).
Who is sponsoring clinical trial NCT01407094?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.